Serum and saliva total tau protein as a marker for relapsing-remitting multiple sclerosis

被引:17
|
作者
Mirzaii-Dizgah, Mohammad-Hossein [1 ]
Mirzaii-Dizgah, Mohammad-Reza [2 ]
Mirzaii-Dizgah, Iraj [3 ]
机构
[1] Aja Univ Med Sci, Student Res Ctr, Sch Dent, Tehran, Iran
[2] Iran Univ Med Sci, Student Res Ctr, Sch Med, Tehran, Iran
[3] Aja Univ Med Sci, Sch Med, Dept Physiol, Tehran, Iran
关键词
Multiple sclerosis; Tau protein; Saliva; Serum; CEREBROSPINAL-FLUID; AXONAL DEGENERATION; BIOLOGICAL MARKERS; PHOSPHORYLATED TAU; CORTISOL LEVEL; BIOMARKERS; CSF; SEVERITY; DAMAGE; BLOOD;
D O I
10.1016/j.mehy.2019.109476
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Multiple sclerosis (MS) is considered as motor and sensory function loss, which results from demyelination and following axonal lesion. Tau protein interferes in the construction and stabilization of microtubules that are needed for axonal transport. We hypothesize that the level of tau protein alters in MS, so we examined the level of total tau protein in serum, stimulated and unstimulated saliva as a suitable biomarker for detecting of relapsing-remitting MS. A case-control study was carried out in 30 healthy women and 30 who suffer MS and were hospitalized in Imam Reza hospital, Tehran, Iran. Total tau protein level was assayed in serum and stimulated and unstimulated whole saliva. Total tau protein was expressed at a lower level in serum of MS patients compared to control groups. The serum total tau protein level negatively correlated with EDSS. There was no significant difference in saliva total tau protein between MS and healthy individuals. Moreover, there was no significant correlation between saliva and serum total tau protein and between saliva total tau protein and EDSS. The serum level of tau protein is lower in MS and it may be considered as a potential biomarker in Multiple sclerosis. However, it seems that tau protein in the saliva isnt a suitable biomarker for detection of MS.
引用
收藏
页数:3
相关论文
共 50 条
  • [21] Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
    Tenorio-Laranga, Jofre
    Coret-Ferrer, Francisco
    Casanova-Estruch, Buenaventura
    Burgal, Maria
    Garcia-Horsman, Arturo
    JOURNAL OF NEUROINFLAMMATION, 2010, 7
  • [22] Tissue factor as a potential coagulative/vascular marker in relapsing-remitting multiple sclerosis
    Mackman, Nigel
    Sachetto, Ana T. A.
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [23] Development of laquinimod for relapsing-remitting multiple sclerosis
    Jeffery, Douglas R.
    FUTURE NEUROLOGY, 2008, 3 (06) : 641 - 648
  • [24] Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
    Menge, Til
    Dubey, Divyanshu
    Warnke, Clemens
    Hartung, Hans-Peter
    Stuve, Olaf
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (10) : 1131 - 1139
  • [25] Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
    Fox, Edward J.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (12) : 1789 - 1797
  • [26] Cognitive Impairment In Relapsing-Remitting Multiple Sclerosis
    Topcular, Baris
    Ozcan, M. Emin
    Kurt, Elif
    Kuscu, Demet Yandim
    Icen, Nilufer Kale
    Sutlas, Pakize Nevin
    Kirbas, Dursun
    Bingol, Ayhan
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2012, 49 (03): : 178 - 182
  • [27] Oral fingolimod for relapsing-remitting multiple sclerosis
    Doggrell, Sheila A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (10) : 1777 - 1781
  • [28] PROGNOSIS OF DISABILITY IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Somilo, O., V
    Kalbus, O., I
    Makarov, S. O.
    Sorokin, A. V.
    Shastun, N. P.
    WORLD OF MEDICINE AND BIOLOGY, 2023, 84 (02): : 147 - 152
  • [29] Executive functions in relapsing-remitting multiple sclerosis
    Elosua, M. Rosa
    Villadangos, Noelia
    APPLIED NEUROPSYCHOLOGY-ADULT, 2023,
  • [30] Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis
    Buscarinu, M. C.
    Romano, S.
    Mechelli, R.
    Umeton, R. Pizzolato
    Ferraldeschi, M.
    Fornasiero, A.
    Renie, R.
    Cerasoli, B.
    Morena, E.
    Romano, C.
    Loizzo, N. D.
    Umeton, R.
    Salvetti, M.
    Ristori, G.
    NEUROTHERAPEUTICS, 2018, 15 (01) : 68 - 74